{"id":"block_63b60dfe3e32c","name":"acf\/block-resource-summary","data":{"resource_summary_0_summary_heading":"Study Background","resource_summary_0_summary_rich_text_module_0_content":"\u2022 Assessing programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) expression plays an important role in identifying patients likely to benefit from anti\u2013programmed death-1\/PD-L1 therapies in advanced cancer, including urothelial carcinoma (UC)\r\n\r\n\u2022 Studies have shown moderate-to-strong interobserver agreement for pathologist assessment of PD-L1 expression on tumor cells, with moderate-to-poor concordance for immune cell scoring1\u20133\r\n\r\n\u2022 Thus, conventional pathologist estimation of whole-slide image scores is a suboptimal approach to obtain reference data for the evaluation of the performance of image-analysis algorithms, especially\r\nfor immune cell scoring","resource_summary_0_summary_rich_text_module_0_button":"","resource_summary_0_summary_rich_text_module":1,"resource_summary_0_summary_document_link":"https:\/\/pathaiwp.wpenginepowered.com\/wp-content\/uploads\/2023\/01\/Copy-of-Beck_PathAI-UC_SITC-2019_04Nov2019.pdf","resource_summary_0_summary_document_button_label":"View Poster","resource_summary_0_summary":"","resource_summary_0_author_heading":"Authors","resource_summary_0_author_rich_text_module_0_content":"Beck et al.","resource_summary_0_author_rich_text_module_0_button":"","resource_summary_0_author_rich_text_module":1,"resource_summary_0_author":"","resource_summary":1,"jump_link_label":""},"align":"","mode":"edit"}
Get In Touch
PathAI Media
Company Contact
Liz Storti
Chief People Officer
Media Contact
Daniel Donato
LifeSci Communications
516-474-0554